Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma

Epidermal growth factor receptor (EGFR) mutants drive lung tumorigenesis and are targeted for therapy. However, resistance to EGFR inhibitors has been observed, in which the mutant EGFR remains active. Thus, it is important to uncover mediators of EGFR mutant-driven lung tumors to develop new treatment strategies. The protein tyrosine phosphatase (PTP) Shp2 mediates EGF signaling. Nevertheless, it is unclear if Shp2 is activated by oncogenic EGFR mutants in lung carcinoma or if inhibiting the Shp2 PTP activity can suppress EGFR mutant-induced lung adenocarcinoma. Here, we generated transgenic mice containing a doxycycline (Dox)-inducible PTP-defective Shp2 mutant (tetO-Shp2CSDA). Using the rat Clara cell secretory protein (CCSP)-rtTA-directed transgene expression in the type II lung pneumocytes of transgenic mice, we found that the Gab1-Shp2 pathway was activated by EGFRL858R in the lungs of transgenic mice. Consistently, the Gab1-Shp2 pathway was activated in human lung adenocarcinoma cells containing mutant EGFR. Importantly, Shp2CSDA inhibited EGFRL858R-induced lung adenocarcinoma in transgenic animals. Analysis of lung tissues showed that Shp2CSDA suppressed Gab1 tyrosine phosphorylation and Gab1-Shp2 association, suggesting that Shp2 modulates a positive feedback loop to regulate its own activity. These results show that inhibition of the Shp2 PTP activity impairs mutant EGFR signaling and suppresses EGFRL858R-driven lung adenocarcinoma.

[1]  Yuan Ren,et al.  SHP2E76K mutant promotes lung tumorigenesis in transgenic mice. , 2014, Carcinogenesis.

[2]  Richard Z. Liu,et al.  JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations , 2013, Scientific Reports.

[3]  J. Turchi,et al.  Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma. , 2013, Biochemical and biophysical research communications.

[4]  M. Lazzara,et al.  Diminished Functional Role and Altered Localization of Shp2 in Non-Small Cell Lung Cancer Cells With Egfr-Activating Mutations , 2012, Oncogene.

[5]  N. Aceto,et al.  Targeting Protein-Tyrosine Phosphatases in Breast Cancer , 2012, Oncotarget.

[6]  Stephen J. Elledge,et al.  Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop , 2012, Nature Medicine.

[7]  M. Rehli,et al.  Critical Role of IRF-8 in Negative Regulation of TLR3 Expression by Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase-2 Activity in Human Myeloid Dendritic Cells , 2011, The Journal of Immunology.

[8]  B. Shen,et al.  SHP2 is a target of the immunosuppressant tautomycetin. , 2011, Chemistry & biology.

[9]  William Pao,et al.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.

[10]  Yuan Ren,et al.  Critical role of Shp2 in tumor growth involving regulation of c-Myc. , 2010, Genes & cancer.

[11]  W. Guida,et al.  Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. , 2010, Biochemical pharmacology.

[12]  Jie Wu,et al.  Targeting protein tyrosine phosphatases for anticancer drug discovery. , 2010, Current pharmaceutical design.

[13]  Keara M. Lane,et al.  Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. , 2010, Cancer research.

[14]  R. Chan,et al.  Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). , 2010, Journal of medicinal chemistry.

[15]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[16]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[17]  B. Neel,et al.  The tyrosine phosphatase Shp2 (PTPN11) in cancer , 2008, Cancer and Metastasis Reviews.

[18]  J. Cheng,et al.  Shp2E76K Mutant Confers Cytokine-independent Survival of TF-1 Myeloid Cells by Up-regulating Bcl-XL* , 2007, Journal of Biological Chemistry.

[19]  W. Pao,et al.  Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors , 2007, PloS one.

[20]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[21]  W. Guida,et al.  Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor , 2006, Molecular Pharmacology.

[22]  P. Jänne,et al.  The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. , 2006, Cancer cell.

[23]  H. Varmus,et al.  Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.

[24]  Songshu Meng,et al.  Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor. , 2005, The Biochemical journal.

[25]  John D. Minna,et al.  Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia , 2004, Cancer Research.

[26]  R. Jove,et al.  Roles of Gab1 and SHP2 in Paxillin Tyrosine Dephosphorylation and Src Activation in Response to Epidermal Growth Factor* , 2004, Journal of Biological Chemistry.

[27]  B. Neel,et al.  Tyrosyl Phosphorylation of Shp2 Is Required for Normal ERK Activation in Response to Some, but Not All, Growth Factors* , 2003, Journal of Biological Chemistry.

[28]  C. Desponts,et al.  Regulation of the Mitogen-activated Protein Kinase Signaling Pathway by SHP2* , 2002, The Journal of Biological Chemistry.

[29]  Jie Wu,et al.  Phosphotyrosines 627 and 659 of Gab1 Constitute a Bisphosphoryl Tyrosine-based Activation Motif (BTAM) Conferring Binding and Activation of SHP2* , 2001, The Journal of Biological Chemistry.

[30]  L. Mei,et al.  Requirement of SHP2 Binding to Grb2-associated Binder-1 for Mitogen-activated Protein Kinase Activation in Response to Lysophosphatidic Acid and Epidermal Growth Factor* , 2000, The Journal of Biological Chemistry.

[31]  J. Tichelaar,et al.  Conditional Expression of Fibroblast Growth Factor-7 in the Developing and Mature Lung* , 2000, The Journal of Biological Chemistry.